Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.74 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | HTR1B | P28222 | 1/20 | 0.71 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806527 | 0.94 | MTNR1A (0.68) | MTNR1AMTNR1BTRPV1HTR1AHTR1B | |
| SCHEMBL3815984 | 0.93 | MTNR1A (0.75) | MTNR1AMTNR1BTRPV1HTR1AHTR1B | |
| SCHEMBL14907346 | 0.91 | MTNR1A (0.67) | MTNR1AMTNR1BTRPV1HTR1AHTR1B | |
| SCHEMBL1129551 | 0.90 | MTNR1A (0.92) | MTNR1AMTNR1BTRPV1HTR1A | |
| SCHEMBL7505689 | 0.90 | MTNR1A (0.92) | MTNR1AMTNR1BTRPV1HTR1A | |
| SCHEMBL8571512 | 0.90 | MTNR1A (0.92) | MTNR1AMTNR1BTRPV1HTR1A | |
| SCHEMBL14907361 | 0.89 | MTNR1A (0.75) | MTNR1AMTNR1BTRPV1HTR1AHTR1B | |
| SCHEMBL14960996 | 0.87 | MTNR1A (0.63) | MTNR1AMTNR1BTRPV1HTR1AHTR1B | |
| SCHEMBL1130207 | 0.86 | TRPV1 (0.80) | MTNR1AMTNR1BTRPV1FAAHPTGS2 | |
| SCHEMBL20648099 | 0.86 | TRPV1 (0.80) | MTNR1AMTNR1BTRPV1FAAHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063492-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | MTNR1A 570/4885MTNR1B 782/4885TRPV1 2188/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | MTNR1A 570/4885MTNR1B 782/4885TRPV1 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.